KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• KRAS mutations are common in colorectal cancer, driving tumor growth via the MAPK pathway.
• KRAS mutations at codons 12, 13, or 61 typically lead to resistance against EGFR inhibitors.
• The role of NF1 in KRAS G13-mutated cancers and EGFR inhibitor response is not fully understood.

Purpose of the Study:

• To investigate the interplay between KRAS G13 mutations, NF1, and response to EGFR inhibitors in colorectal cancer.
• To elucidate the structural and functional mechanisms of neurofibromin-mediated GTP hydrolysis in KRAS G13D.

Main Methods:

• Analysis of KRAS and NF1 mutation co-occurrence in colorectal cancer datasets.
• Biochemical assays to assess GTP hydrolysis by neurofibromin in complex with KRAS G13D.
• Structural biology studies of KRAS-neurofibromin complexes.

Main Results:

• KRAS G13-mutated colorectal cancers frequently exhibit NF1 co-mutations, unlike cancers with KRAS codon 12 or 61 mutations.
• Neurofibromin directly hydrolyzes GTP in complex with KRAS G13D.
• KRAS G13D-mutated cancer cells demonstrate EGFR inhibitor sensitivity dependent on neurofibromin function.
• Structural data reveals the mechanism of neurofibromin-mediated GTP hydrolysis for KRAS G13D.

Conclusions:

• KRAS G13D is responsive to neurofibromin-stimulated GTP hydrolysis.
• A subset of KRAS G13-mutated colorectal cancers with functional neurofibromin may benefit from EGFR therapies.
• This study provides a mechanistic basis for predicting EGFR inhibitor response in specific KRAS-mutated colorectal cancers.